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Abstract
Background: To support the evaluation of the 2010-15 National Plan for Measles and Congenital Rubella
Elimination, the authors designed and performed a serosurveillance survey to verify the immunity/susceptibility rate
against rubella among Apulian young adults.
Methods: The study was carried out from May 2011 to June 2012 in the Department of Transfusion Medicine/Blood
Bank of Policlinico General Hospital in Bari. Subjects were enrolled by a convenience sampling. For each
enrolled patient a 5 ml serum sample was collected and tested for anti-rubella IgG. The geometrical means
(GMT) of anti-rubella IgG was calculated. T student test or ANOVA test, when appropriate, was used to
compare the means of age per gender and GMT of anti-rubella IgG titres per age classes. Chi-square test
was used to compare the proportion of anti-rubella IgG positive subjects per gender and per age classes.
For all tests, a p value <0.05 was considered as significant.
Results: At the end of the study 1764 subjects were enrolled, 1362 (77.2%) of which were male. The mean
age was 38.4 ± 11.7 years (range: 17-65). 86.7% (95% CI = 85.0-88.2) had a positive titre of anti-rubella IgG.
GMT of anti-rubella IgG titre was 4.3.
The proportion of positive subjects was of 76.8% (n = 279/363; 95% CI = 72.2-81.1) in persons aged 18-26
years; 88.1% (n = 310/352; 95% CI = 84.2-91.3) in 27-35 year-old people; 88.5% (n = 464/524; 95% CI = 85.5-91.1)
in 36-45 year-old people; 90.7% (n = 350/386; 95% CI = 87.3-93.4) among people aged 46-55 years and 90.6%
(n = 126/139; 95% CI = 84.5-94.9) in 55-65 year-old people (Chi-square = 39.7; p < 0.0001). GMT of anti-rubella
IgG titre was 4.3 (4.3 in male and 4.2 in female, t = 2.2; p = 0.03) and seems to differ dividing the enrolled
subjects by age group (F = 14.3; p < 0.0001).
Conclusions: According to our data, too many women of child-bearing age are still unprotected from rubella
in the elimination era and in this scenario the public health efforts should be oriented to catch-up activities.
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Background
The control of rubella is actually a global public health
issue, because rubella virus infection during pregnancy
may lead to fetal death or premature delivery, or may
cause Congenital Rubella Syndrome (CRS), a condition
which can involve all fetal organs, resulting in cataracts,
deafness, heart defects, mental retardation. Congenital
infections from rubella virus accounted for more than
100,000 cases worldwide in 1996, especially in countries
with high rates of susceptibility to rubella among women
of childbearing age [1].
A live-attenuated vaccine against rubella is available
since 1960 [2] and in 2003 WHO reported that 131/215
countries/territories included rubella vaccine to their
national immunization schedule. In 2002 two WHO
regions, the Americas and Europe, established regional
targets for elimination of rubella and CRS by the year
2010 [3–6].
A 2005–2010 strategic plan for eliminating measles
and rubella and preventing CRS was launched by
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WHO European Region and within December 2012
all European countries introduced rubella-containing
vaccines in their routine immunization programs;
despite these public health efforts rubella is still cir-
culating in Europe. The European Region number of
rubella cases decreased from 804,567 in 1999 to
10,448 in 2010. Between 1990 and 2010, 467 cases of
CRS were reported by 24 member states [7].
In Italy, the goal of rubella elimination and CRS pre-
vention by year 2007 was first defined in the National
Plan of Measles and Congenital Rubella Elimination
2003–2007 (PNEMoRC). Because the 2007 goal of elim-
ination was not reached, the new PNEMoRC 2010–2015
deferred its achievement to the year 2015 and
highlighted the need to strengthen the surveillance and
reduce to less than 5% the susceptibility rate to rubella
among women in childbearing age [8, 9]. After the PNE-
MoRC adoption, the vaccination coverage for rubella
progressively increased; the 2013 national coverage
assessed in children aged 24 months was 88% [10].
Immunization coverage of adolescents and adults is not
routinely measured in Italy but, according to an epi-
cluster survey conducted on 2008 in 18 of the 21 Italian
regions, rubella vaccination coverage was 75% in
16 year-old adolescents [11].
The goal to reduce susceptibility rate to rubella to
less than 5% among women in childbearing age has
not been achieved yet and from 2005 to 2013 a total
of 75 congenital rubella infections were reported in
Italy; the national annual mean incidence was 1.5/
100,000 live births [12].
Apulia is a region of the South of Italy with about
4 millions of inhabitants; according to PNEMoRc, in
2003 in Apulia an active offer strategy of rubella vac-
cination (using measles-mumps-rubella MMR vac-
cine) was implemented and immunization coverage
progressively increased reaching 90%, but did not
achieve the target coverage (95%) established by
PNEMoRC [13]. From 2003 to 2011, one CRS, two
confirmed and four suspected congenital infections
and seven cases of rubella in pregnancy were
observed in Apulia [14].
To support the evaluation of the 2010-15 PNEMoRC,
the authors designed a seroprevalence survey to test the
immunity/susceptibility rate against rubella among
Apulian young adults. Serological surveillance is an im-
portant tool for the evaluation of vaccination programs
as it monitors immunity status in the population and
provides useful information to identify additional control
measures, in order to the possible adoption of a third
PNEMoRC. Moreover serological surveillance data are
supplemental to coverage data and useful to compensate
for many limitations of passive disease reporting systems
for rubella. Passive reporting systems are often
unreliable due to under notification of clinical cases and
under diagnosis of subclinical cases which are estimated
to be up to 50% of cases [15].
Methods
The study was carried out from May 2011 to June 2012
in the Department of Transfusion Medicine/Blood Bank
of Policlinico General Hospital in Bari.
Subjects were enrolled by a convenience sampling. A
physician explained the aim of the study to blood
donors; written informed consent was requested and
obtained from blood donors who accepted to participate
in the survey. The protocol of the study has been ap-
proved by the Regional Committee for the Epidemiology
(Osservatorio Epidemiologico Regione Puglia). In ac-
cordance with Apulian Regional Laws, permission from
the Ethics Commitee to carry out this study was not
necessary given that both data and sera from patients
were collected for routine diagnostic testing. The re-
search was carried out in accordance with the Helsinky
declaration.
Sample size was established considering the 2012 dis-
tribution of Apulian population by age groups (18-26;
27-35; 36-45; 46-55; 56-65) [16], using seroprevalence
data from the first 100 enrolled subjects with a margin
of error of 5% and a confidence interval of 95%. Age
ranges were established in relation to the target cohort
of MMR vaccination strategies (universal mass vaccin-
ation of all new-borns; catch-up strategies); older
subjects were also enrolled to compare the sero-
epidemiology of rubella in pre and post vaccination era.
For each enrolled patient we collected a 5 ml serum
sample. All collected sera were tested for Anti-rubella
virus IgG using the LIAISON® Rubella IgG chemilumin-
escence immunoassay (CLIA), a quantitative method.
This is an indirect test performed with a standardized
commercial method (DiaSorin, Saluggia, Italy) [17].
The samples with a concentration > 11 IU/mL are con-
sidered reactive (positive). In case of test with a border-
line value, the test was repeated.
For each enrolled subjects, we completed a standard-
ized form reporting age, gender, results of laboratory
test. Forms were computerized using a database created
by FileMaker Pro and data were analysed by STATA
MP11.
We calculated the geometrical means (GMT) of anti-
rubella IgG. T student test or ANOVA test, when appro-
priate, was used to compare the means of age per gender
and GMT of anti-rubella IgG titres per age classes. Chi-
square test was used to compare the proportion of anti-
rubella IgG positive subjects per gender and per age
classes. Linear regression was used to verify the correl-
ation between age and anti-rubella IgG titre. For all
tests, a p value <0.05 was considered as significant.
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Results
At the end of the study 1764 subjects were enrolled,
1362 (77.2%) of which were male. The mean age was
38.4 ± 11.7 years (range: 17-65), higher in male (39.4 ±
11.4) than in female (35.0 ± 12.1; t = 6.69; p < 0.0001).
Table 1 shows the distribution of enrolled subjects by
age group and gender.
86.7% (95% CI = 85.0-88.2) of enrolled subject pre-
sented a titre of anti-rubella IgG >11 IU/mL. This per-
centage was higher in males (n = 1193/1362; 87.6%; 95%
CI = 85.7-89.3) than in females (n = 336/402; 83.6%; 95%
CI = 79.6-87.1; chi-square = 4.3; p = 0.04).
The proportion of positive subjects was of 76.8% (n =
279/363; 95% CI = 72.2-81.1) in persons aged 18-26
years; 88.1% (n = 310/352; 95% CI = 84.2-91.3) in 27-35
year-old people; 88.5% (n = 464/524; 95% CI = 85.5-91.1)
in 36-45 year-old people; 90.7% (n = 350/386; 95% CI =
87.3-93.4) among people aged 46-55 years and 90.6%
(n = 126/139; 95% CI = 84.5-94.9) in 55-65 year-old
people (Chi-square = 39.7; p < 0.0001; Fig. 1).
GMT of anti-rubella IgG titre was 4.3 (4.3 in male
and 4.2 in female, t = 2.2; p = 0.03) and seems to differ
dividing the enrolled subjects by age group (Fig. 1; F =
14.3; p < 0.0001). There is no correlation between age and
anti-rubella IgG titre (r2 = 0.0006; F = 0.02; p = 0.87).
Discussion
Our study showed a lack of immunity against rubella
among Apulian young adults from 18 to 26 years of age;
in this age group the proportion of susceptible subjects
is more than 20%, in the other age groups the rate
accounted 10-12%. The subjects with lack of immunity
were born between 1988 and 1994, but only people born
between 1990 and 1996 were a target of the 2003/2004
catch-up vaccination campaign planned by 2003
PNEMoRC.
A great proportion of young individuals showed
lower levels of protective immunity, probably because
they missed out on vaccination in catch up pro-
grammes. In fact, current coverage data for Apulian
catch up target cohorts were around 70% [14]. This
coverage determined a reduction in the circulation of
wild-type infection, that could cause a lack of immun-
ity among young adults and an increase of median
age of infection.
PNEMoRC also recommended the free of charge offer
of MMR vaccine to all susceptible females in childbear-
ing age, but no specific actions for the active offer took
place in Italian regions. The vaccination strategy based
on passive offer seemed not consistent with the PNE-
MORC objective to reduce the percentage of susceptible
females <5% [12].
Considering all enrolled females in childbearing age
(18-49 years), the percentages of immune subjects is of
82.3% (95% CI = 77.9-86.2).
Our results quite differ from other studies carried out
in countries that implemented Universal Mass Vaccin-
ation Program. In Australia, a serosurvey performed in
2001 (3 years after the beginning of Australian Measles
Control Campaign) showed that the percentage of 16-39
years old subjects immune for rubella was 97% [18]. A
similar rate was reported in the Netherlands where the
rubella vaccine was actively offered to 11-years adoles-
cents since 1974 and in 1987 the MMR vaccination was
implemented in the national immunization program. In
fact a 2014 survey showed a seroimmunity rate >90%
among subjects aged >18 years [19]. In these countries
national immunization campaigns reached target
immunization coverage.
Our regional situation seems to remind the situation
of USA in 1988-1994, when a serosurveillance study
reported a rubella susceptibility rate of 22% among
subjects of 18-24 years old [20]. Similarly to USA data,
our results indicate the interaction between the
immunization program and the natural history of
rubella. In fact, in USA the rubella immunization pro-
gram began in 1971 while in Italy in 2003, both the two
studies were carried out 10-15 years after the beginning
of immunization programs and results are globally
concordant.
Bechini et al. carried out a serosurvey about ru-
bella in Tuscany in 2012 and seroprevalence in this
study (that involved a bigger number of females) is
higher than in our survey, achieving 90%; this differ-
ence could be related to the enrolment of younger
subjects (<18 years), that we did not consider in our
sample [21].
The lesson learned is that in the elimination era too
many women of childbearing age are still unprotected
from rubella and this is consistent with the observation
of some cases of CRS in Apulia in the last few years
[14]. This could be related to low vaccine acceptance,
which is lower mostly in the first years after the intro-
duction of new vaccines, to insufficient management of
vaccination strategies and to inappropriate perception by
Table 1 Distribution of enrolled subjects by age group and
gender
Age group Female Male Total
n % n % n %
18-26 137 34.1 226 16.6 363 20.5
27-35 81 20.2 271 19.9 352 20.0
36-45 85 21.1 439 32.2 524 29.7
46-55 82 20.4 304 22.3 386 21.9
56-65 17 4.2 122 9 139 7.9
Total 402 1362 1764
Chi-square = 69.8; p < 0.001
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general population and health care workers of the risk of
vaccine-preventable diseases [22].
In this scenario, the public health efforts should be
oriented to catch-up activities in order to reduce the rate
of susceptible young adults, above all women of child-
bearing age. Gynaecologists and General Practitioners
should be encouraged to actively propose the rubella
screening among women of childbearing age before they
become pregnant, in order to identify those who lack
rubella antibodies, whether acquired as the result of
vaccination or natural infection.
The childbearing age susceptible women immunization
is indeed a priority to be pursued in all possible occasions,
especially in the postpartum days and for immigrant
women. Rubella vaccination should also be administered
in the hospitals before the patient discharge and the
recommendation to get the rubella vaccination should
be reported in the dismissal letter when it is not pos-
sible to vaccine during the hospitalization. Another
opportunity to check rubella immunity status of the
mothers is the access to the vaccination service for
their own child immunization and health care
workers should be encouraged to suggest mothers to
investigate their immunity status during the pre-
vaccination interview.
Finally an active surveillance based on laboratories
that perform rubella immunity test should be
planned; laboratories should notify to Public Health
Authority every woman in childbearing age with a
negative test and Public Health Authority should ac-
tive propose to these women the immunization
against rubella.
Future studies should investigate the effectiveness of
this actions to reduce the rubella susceptibility rate
among young women and decrease CRS, theorized in
national and international recommendations, but actu-
ally not largely implemented.
Conclusion
In conclusion, our sero-survey showed a lack of immun-
ity against rubella among Apulian young adults from 18
to 26 years of age. According to our data, too many
women of child-bearing age are still unprotected from
rubella in the elimination era and in this scenario the
public health efforts should be oriented to catch-up
activities.
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Fig. 1 Proportion of anti-rubella IgG positive subjects and anti-rubella IgG GMT, by age group and gender. Red columns: % of anti-rubella IgG
positive females. Blue columns: % of anti-rubella IgG positive males. Green line: anti-rubella IgG GMT in females. Purple line: anti-rubella IgG GMT
in males
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